Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study

Wang Li¹,²†, Lu-Jun Shen¹,²†, Tao Chen³, Xu-Qi Sun²,³, Ying Zhang²,³, Ming Wu²,³, Wan-Hong Shu²,³, Chen Chen¹,⁴, Chang-Chuan Pan⁵, Yun-Fei Xia¹,⁴ and Pei-Hong Wu¹,²*  

Abstract  
Background: Although the prognostic impact of body mass index (BMI) in patients with non-metastatic nasopharyngeal carcinoma (NPC) had been extensively studied, its effect among metastatic NPC patients remains unknown. The purpose of this study was to evaluate the prognostic effect of BMI in patients with metastatic NPC.  
Methods: We retrospectively studied 819 patients who were diagnosed with distant metastasis from NPC and received treatment between 1998 and 2007. The patients were divided into three subgroups according to the World Health Organization classifications for Asian populations: underweight (BMI < 18.5 kg/m²), normal weight (BMI 18.5–22.9 kg/m²), and overweight/obese (BMI ≥ 23.0 kg/m²). The associations of BMI with overall survival (OS) and progression-free survival (PFS) were determined by Cox regression analysis.  
Results: Of the 819 patients, 168 (20.5%) were underweight, 431 (52.6%) were normal weight, and 220 (26.9%) were overweight/obese. Multivariate analysis adjusted for covariates showed that overweight/obese patients had a longer OS than underweight patients [hazard ratio (HR), 0.64; 95% confidence interval (CI), 0.49–0.84] and normal weight patients (HR, 0.72; 95% CI, 0.57–0.90); no significant difference in PFS was observed among these three groups (P = 0.407). Moreover, in stratified analysis, no statistically significant differences in the effect of overweight/obese status among different subgroups were observed.  
Conclusion: For patients with metastatic NPC, overweight/obese status was associated with longer OS but not longer PFS compared with underweight or normal weight status.  
Keywords: Nasopharyngeal carcinoma, Body mass index, Metastasis, Prognosis  

Background  
Nasopharyngeal carcinoma (NPC) is an endemic head and neck epithelial malignancy, with the highest incidence rate in Southeast Asia [1–3]. Although improvements in radiation techniques and chemotherapy regimens have led to more effective treatments for NPC, 15%–42% of patients still have treatment failures due to distant metastases [4–7]. Once metastasis is diagnosed, the prognosis of patients who are receiving palliative chemotherapy is very poor [8, 9]. Identifying prognostic factors for these patients may lead to the development of new clinical interventions to improve survival.  
Body mass index (BMI) is a simple weight-for-height calculation that is commonly used to evaluate the nutritional status in adults. Approximately 10% of patients with non-metastatic NPC are underweight at diagnosis; in terms of probability of recurrence, metastasis, and overall mortality, they have worse outcomes than...
non-underweight patients [10, 11]. On the other hand, higher BMI seems to be associated with favorable prognosis. In a recent published study of NPC patients, Shen et al. [11] found that the hazard ratio (HR) for death was 0.66 [95% confidence interval (CI) 0.48–0.90] for overweight patients and 0.47 (95% CI 0.23–0.97) for obese patients compared with the baseline of normal weight or underweight patients. Although many studies have been conducted in patients with non-metastatic NPC, none has specifically evaluated the prognostic effect of BMI in patients with metastatic NPC. Long-term palliative chemotherapy can greatly impair the nutritional status of patients with metastatic NPC; therefore, understanding the prognostic effect of BMI may lead to better treatment planning.

In the present study, we investigated the prognostic effects of BMI in patients with metastatic NPC who received systemic chemotherapy. Our previous study showed that NPC patients with different metastatic sites and different numbers of lesions appeared to be a very heterogeneous group in terms of survival [12]. Thus, we additionally performed a subgroup analysis to test the consistency of the effect of BMI.

**Patients and methods**

**Patients**

We reviewed the medical records of 1005 NPC patients with distant metastasis who were treated at Sun Yat-sen University Cancer Center between January 1998 and December 2007. The inclusion criteria included (1) histological or radiological confirmation of distant metastatic lesion(s); (2) Eastern Cooperative Oncology Group performance status of grade 2 or lower; and (3) received at least one cycle of cisplatin-based chemotherapy as first-line treatment. Exclusion criteria were either of the following: (1) Missing weight measurement at baseline and (2) younger than 18 years. The Hospital Ethics Committee of Sun Yat-sen University Cancer Center approved this study.

**Definition**

Primary diseases were staged according to the Union of International Cancer Control (UICC) staging system (6th edition) [13]. To define whether patients presented with distant metastasis when first diagnosed with NPC, metastasis onset was categorized as synchronous or metachronous. The metastatic site, number of metastatic organs, and number of metastases referred to the extent of disease at the time of diagnosis.

Patients’ baseline body weight was measured within 14 days of the start of treatment after metastasis was diagnosed. BMI (kg/m²) was categorized according to the World Health Organization recommendations for Asian populations [14]. Because the number of obese patients was relatively few (20 patients), we merged overweight and obese patients and obtained three BMI subgroups: underweight (<18.5 kg/m²), normal weight (18.5–22.9 kg/m²), and overweight/obese (≥23.0 kg/m²).

**Treatment**

Most patients who presented with synchronous metastasis at initial NPC diagnosis received a cisplatin plus 5-fluorouracil (5-FU) chemotherapy regimen (known as the PF regimen) before concurrent chemoradiotherapy. The concurrent chemotherapy regimen was either 5-FU plus cisplatin or cisplatin alone. The 5-FU plus cisplatin regimen was 70–100 mg/m² of cisplatin on day 1 plus 500–750 mg/m² of 5-FU from day 2 to day 5 every 3–4 weeks, for 2–3 cycles; the cisplatin regimen was 30–40 mg/m² of cisplatin every week, for 4–6 cycles. For patients who had metachronous metastasis after primary treatment, the first-line regimen was almost exclusively platinum-based—cisplatin in combination with 4–6 cycles of one or two of the following drugs: 5-FU, paclitaxel, gemcitabine, and bleomycin. The patients with progression underwent more than one-line chemotherapy regimen. Treatment discontinuation occurred at patient request or for unacceptable drug toxicity. Local therapies such as surgery, radiotherapy, interventional embolization, and radiofrequency ablation were available for those patients who still had metastatic lesions after chemotherapy.

**Follow-up and endpoints**

During palliative chemotherapy, patients were evaluated by computed tomography or magnetic resonance imaging for response every two cycles and then every 3 months until death or the last follow-up (June 30, 2014). The primary outcomes were overall survival (OS) and progression-free survival (PFS). OS was defined as time from the diagnosis of distant metastasis to death by any cause. PFS was defined as time from the diagnosis of distant metastasis to tumor progression or death by cancer.

**Statistical analyses**

The Pearson χ² test was used to compare the categorical variables among groups respectively. OS and PFS rates were estimated using the Kaplan–Meier method and compared among the BMI subgroups by the log-rank test. The multiple-adjusted Cox model was used to determine the effect of BMI on survival; covariates included age, sex, UICC T category, UICC N category, metastatic onset, lung metastasis (absent versus present), liver metastasis (absent versus present), bone metastasis (absent versus present), single lesion (no versus yes),
number of involved sites, and treatment modality. To
test the consistency of the favorable effect associated
with overweight/obese status, a subgroup analysis using
the multiple-adjusted Cox model was further conducted,
with all the covariates, except for stratification factor,
included. The Cox regression model, including two main
effect parameters and their interaction effect parameters,
was used to test the interaction effect between BMI and
the other covariates. \( P \) values less than 0.05 were con-
sidered statistically significant. Statistical analyses were
performed using the SPSS 20.0 software (IBM SPSS Inc.,
Chicago, IL, USA).

Results

Patient characteristics
A total of 819 patients who met the inclusion criteria
were included in this study. Table 1 shows the baseline
characteristics of the 819 patients with metastatic NPC.
The median age was 45 years (range 18–78 years). Of
these patients, 772 (94.3%) had undifferentiated non-
keratinizing carcinoma, 31 (3.8%) had differentiated
non-keratinizing carcinoma, and 16 (1.9%) had other
types; 272 (33.2%) had synchronous metastasis, and 547
(66.8%) had metachronous metastasis. Two hundred
seventy-four (33.5%) patients had more than one meta-
static site. All patients in either the synchronous or the
metachronous group received at least one cycle of plat-




BMI and survival
For the 819 patients included in this analysis, 653 (79.7%)
progressions and 498 (60.8%) deaths were recorded. The
1-, 3-, and 5-year OS rates for the whole patient popu-
lation were 81.4%, 33.7% and 16.7%, respectively; the 1-,
3-, and 5-year PFS rates were 47.6%, 16.6% and 7.1%,
respectively.

In univariate analysis, overweight/obese patients had
a significantly higher 5-year OS rate than underweight
patients (25.9% vs. 12.3%, \( P < 0.001 \)) and normal weight
patients (25.9% vs. 14.6%, \( P = 0.008 \)), whereas no sig-
nificant difference was observed between underweight
and normal weight patients (\( P = 0.112 \); Fig. 1a). In con-
trast, overweight/obese patients had significantly higher
5-year PFS rates than underweight patients (11.9% vs.
3.5%, \( P = 0.042 \)), whereas no significant differences
were observed between normal weight and overweight/
obese patients (\( P = 0.333 \)) or between normal weight and
underweight patients (\( P = 0.141 \) (Fig. 1b). Other factors
influencing OS and PFS are listed in Tables 2 and 3.

Multiple-adjusted Cox model was used in multi vari-
ate analysis with covariates including age, sex, UICC
T category, UICC N category, metastatic onset, lung
metastasis, liver metastasis, bone metastasis, solitary
lesion, number of involved sites, and treatment modal-
ity. Collinearity for all the adjusting variables was tested,
resulting in variance inflation factors (1.02–2.62) and tol-
erances (0.44–0.98) within acceptable regression limits.
Overweight/obese patients had a significantly lower risk
of death compared with underweight patients (HR 0.62;
95% CI 0.48–0.81 Table 2) and normal weight patients
(HR 0.72; 95% CI 0.57–0.90), whereas no significant dif-
fERENCE was observed in OS between normal weight and
underweight patients (HR 0.84; 95% CI 0.67–1.04). The
other significant prognostic factors for OS included age,
UICC N category, metastasis onset, liver metastasis, and
treatment modality. In multiple-adjusted analysis for
PFS, BMI was not significant; the significant prognostic
factors included UICC N category, liver metastasis, bone
metastasis, and treatment modality (Table 3).

To examine the consistency of the effect of BMI in
patients with metastatic NPC, we conducted further
stratified analysis using the multiple-adjusted model
(Table 4). No statistically significant differences were
observed in the effects of overweight/obese status on
other explanatory variables, but the effect seemed more
pronounced in NPC patients with bone metastasis and
in patients receiving chemotherapy only. The magnitude
of favorable effect of overweight/obese status was similar
across the age, sex, UICC T category, UICC N category,
and metastasis onset categories.

Discussion
In the present study, we found that, in patients with met-
astatic NPC, BMI was an independent prognostic factor
for OS but not for PFS. Patients who were overweight/
obese had a significantly lower risk of death than under-
weight and normal weight patients; this effect was more
pronounced in patients with bone metastasis and in
those who received chemotherapy only.
Several studies reported on the prognostic effect of BMI in patients with NPC [6, 10, 15], and there is increasing awareness that this effect may vary in different subgroups. Huang et al. [16] retrospectively analyzed the data of 400 patients with stage III or stage IVa NPC who received chemoradiotherapy. They found that, compared with normal weight patients, overweight patients had a more favorable OS (HR 0.57; 95% CI 0.39–0.85) and distant failure-free survival (HR 0.61; 95% CI 0.40–0.92) [16]. This finding suggests that nutritional status might also play a critical role in advanced-stage or even end-stage NPC patients. A recent study by Pan et al. [17] evaluated the prognostic effect of anatomic features of metastases in patients with metastatic NPC. They showed that, in the synchronous metastatic group, underweight status was an unfavorable prognostic factor, whereas in the metachronous group, its effect failed to reach significance [17]. However, in their study, covariates associated with the treatment modality were not included in the analysis, and BMI level was simply dichotomized (<18.5 vs. ≥18.5 kg/m²), which impeded further interpretation. In our study, we observed a markedly higher OS rate (but Table 1 Baseline characteristics by BMI level of patients with metastatic nasopharyngeal carcinoma (NPC)

| Variable                        | All   | Underweight | Normal weight | Overweight/obese | P value* |
|--------------------------------|-------|-------------|---------------|------------------|---------|
| Total                          | 819   | 168         | 431           | 220              |         |
| Age (years)                    |       |             |               |                  |         |
| <45                            | 419 (51.2) | 97 (57.7) | 223 (51.7)    | 99 (45.0)        | 0.043   |
| ≥45                            | 400 (48.8) | 71 (42.3)  | 208 (48.3)    | 121 (55.0)       |         |
| Sex                            |       |             |               |                  | 0.688   |
| Men                            | 681 (83.2) | 139 (82.7) | 355 (82.4)    | 187 (85.0)       |         |
| Women                          | 138 (16.8) | 29 (17.3)  | 76 (17.6)     | 33 (15.0)        |         |
| UICC T category                |       |             |               |                  | 0.504   |
| T1–2                           | 369 (45.1) | 76 (45.2)  | 201 (46.6)    | 92 (41.8)        |         |
| T3–4                           | 450 (54.9) | 92 (54.8)  | 230 (53.4)    | 128 (58.2)       |         |
| UICC N category                |       |             |               |                  | 0.221   |
| N0–1                           | 417 (50.9) | 89 (53.0)  | 227 (52.7)    | 101 (45.9)       | <0.001  |
| N2–3                           | 402 (49.1) | 79 (47.0)  | 204 (47.3)    | 119 (54.1)       |         |
| Metastasis onset                |       |             |               |                  |         |
| Synchronous                    | 272 (33.2) | 42 (25.0)  | 135 (31.3)    | 95 (43.2)        |         |
| Metachronous                   | 547 (66.8) | 126 (75.0) | 296 (68.7)    | 125 (56.8)       |         |
| Lung metastasis                |       |             |               |                  | 0.709   |
| Absent                         | 469 (57.3) | 96 (57.1)  | 242 (56.1)    | 131 (59.5)       |         |
| Present                        | 350 (42.7) | 72 (42.9)  | 189 (43.9)    | 89 (40.5)        |         |
| Liver metastasis               |       |             |               |                  | 0.201   |
| Absent                         | 574 (70.1) | 118 (70.2) | 292 (67.7)    | 164 (74.5)       |         |
| Present                        | 245 (29.9) | 50 (29.8)  | 139 (32.3)    | 56 (25.5)        |         |
| Bone metastasis                |       |             |               |                  | 0.032   |
| Absent                         | 382 (46.6) | 67 (39.9)  | 219 (50.8)    | 96 (43.6)        |         |
| Present                        | 437 (53.4) | 101 (60.1) | 212 (49.2)    | 124 (56.4)       |         |
| Solitary lesion                |       |             |               |                  | 0.010   |
| No                             | 701 (85.6) | 155 (92.3) | 356 (82.6)    | 190 (86.4)       |         |
| Yes                            | 118 (14.4) | 13 (7.7)   | 75 (17.4)     | 30 (13.6)        |         |
| Number of involved sites       |       |             |               |                  | 0.592   |
| One                            | 545 (66.5) | 107 (63.7) | 287 (66.6)    | 151 (68.6)       |         |
| Two or more                    | 274 (33.5) | 61 (36.3)  | 144 (33.4)    | 69 (31.4)        |         |
| Treatment modality             |       |             |               |                  | 0.322   |
| CT                             | 607 (74.1) | 132 (78.6) | 313 (72.6)    | 162 (73.6)       |         |
| CT + LT                        | 212 (25.9) | 36 (21.4)  | 118 (27.4)    | 58 (26.4)        |         |

All values are presented as the number of cases followed by percentage in the parentheses

BMI body mass index; UICC Union of International Cancer Control; CT chemotherapy; LT local therapy

* P values were computed excluding patients without information in the corresponding variable.

Several studies reported on the prognostic effect of BMI in patients with NPC [6, 10, 15], and there is increasing awareness that this effect may vary in different subgroups. Huang et al. [16] retrospectively analyzed the data of 400 patients with stage III or stage IVa NPC who received chemoradiotherapy. They found that, compared with normal weight patients, overweight patients had a more favorable OS (HR 0.57; 95% CI 0.39–0.85) and distant failure-free survival (HR 0.61; 95% CI 0.40–0.92) [16]. This finding suggests that nutritional status might also play a critical role in advanced-stage or even end-stage NPC patients. A recent study by Pan et al. [17] evaluated the prognostic effect of anatomic features of metastases in patients with metastatic NPC. They showed that, in the synchronous metastatic group, underweight status was an unfavorable prognostic factor, whereas in the metachronous group, its effect failed to reach significance [17]. However, in their study, covariates associated with the treatment modality were not included in the analysis, and BMI level was simply dichotomized (<18.5 vs. ≥18.5 kg/m²), which impeded further interpretation. In our study, we observed a markedly higher OS rate (but
not a higher PFS rate) in overweight/obese patients compared with underweight or normal weight patients. Since we observed a differential distribution for age, metastasis onset, bone metastasis, and the number of lesions in the BMI subgroups, we conducted a multiple-adjusted analysis and found that the BMI level was still significant in predicting OS, with its effect consistent in both the synchronous metastasis and the metachronous metastasis groups. In aggregate, these results suggest that BMI level is an important prognostic factor in patients with metastatic NPC.

The reason for the prognostic effect of BMI in patients with metastatic NPC may mainly involve malnutrition. Underweight head and neck cancer patients are more susceptible to malnutrition and even cachexia—both known to be associated with compromised immunity [18, 19], reduced tolerance to oncologic therapies [20, 21], and poor treatment outcome [22–25]—than patients with higher BMI. By contrast, patients who are overweight or obese may tolerate therapy better and therefore may have better outcomes. In addition, comorbidities like diabetes, chronic obstructive pulmonary disease, and cardiovascular diseases could worsen the prognosis of NPC patients; these comorbidities might also lead to low BMI [2, 26]. A recent study of 1001 newly diagnosed NPC patients showed that, before radiation treatment, 15.5% of elderly patients (>70 years old) presented with moderate to severe comorbidities (Adult Comorbidity Evaluation-27 score >2); these patients had lower OS rate (HR 2.63; 95% CI 1.45–4.76) than patients who had no comorbidities or mild comorbidities. However, in our population, the proportion of elderly patients was rather small (16 patients; 1.9%); thus, this may not be an important consideration [27].

We found that pre-treatment BMI level was independently associated with OS in patients with metastatic NPC, but it is interesting that BMI did not have an effect on PFS. Currently, no curative therapy is available for metastatic NPC. One plausible explanation for this may be that, for patients with metastatic NPC, being overweight or obese does not guarantee that any given oncologic therapy will have improved efficacy; being overweight or obese may, however, associate with a higher tolerance to continuous treatment, resulting in superior long-term benefits [9, 28]. Moreover, this may be partly supported by our preliminary data that the overweight/obese group received more cycles of palliative chemotherapy after metastasis diagnosis than the other two groups (overweight/obese: median, five cycles; normal weight: median, three cycles; underweight: median, four cycles).

Our study showed the clinical course of a large cohort of patients with metastatic NPC. OS varied among the patients (range 1–120 months), and the 5-year OS rates after metastasis for overweight/obese, normal weight, and underweight patients were 25.9%, 14.6% and 12.3%, respectively. These results indicate that long-term survival is possible for some patients and that more aggressive multimodality treatment should be encouraged for patients with high baseline BMI. Interestingly, the unfavorable prognostic effect of underweight status in patients who received chemotherapy combined with local therapy was absent; this suggests that patients with localized metastatic lesions who receive local therapy might overcome the negative...
Effect of low baseline BMI. In addition, since patients with higher BMI levels may be more tolerant to intensive treatment, and since a higher dosage or denser interval of chemotherapy could potentially be beneficial, future clinical trials that investigate the optimal dosage and interval of chemotherapy are important and warranted.

Our results suggest that, for patients with metastatic NPC, certain interventions that target underweight status or malnutrition might be beneficial. For the past decade, ample evidence has shown that, for patients with head and neck cancer, adequate nutrition support before and during treatment can decrease the severity of adverse effects, minimize weight loss, and improve outcomes [29, 30].

Studies have suggested that patients with head and neck cancer who have a BMI less than 20 kg/m² should receive further assessment, intensive counselling, and nutrition support [31–33]. However, owing to a lack of high-quality studies, recent reviews were not able to provide evidence for or against a role of nutrition support in head neck cancer patients [31, 34, 35]. Additionally, no study has specifically focused on the effect of nutrition intervention on patients with NPC. Therefore, multicenter randomized controlled trials and well-designed observation studies that examine nutrition intervention are needed.

This study had several limitations. First, it was a retrospective study. Second, BMI was measured only at the diagnosis of metastasis, and further changes were not considered owing to the difficulty of assessing changes influenced by adverse effects of different chemotherapy/

---

### Table 2 Univariate and multivariate analyses of covariates associated with overall survival in patients with metastatic NPC

| Variable | Univariate | Multivariate |
|----------|------------|--------------|
|          | HR (95% CI) | P | HR (95% CI) | P |
| Age (<45 years vs. ≥45 years) | 1.23 (1.03–1.46) | 0.023 | 1.28 (1.07–1.53) | 0.007 |
| Sex (men vs. women) | 1.02 (0.81–1.29) | 0.870 | 1.01 (0.79–1.27) | 0.958 |
| UICC T category (T1–2 vs. T3–4) | 0.91 (0.77–1.09) | 0.310 | 0.94 (0.78–1.12) | 0.480 |
| UICC N category (N0–1 vs. N2–3) | 1.33 (1.12–1.59) | 0.001 | 1.39 (1.16–1.67) | <0.001 |
| Metastasis onset (synchronous vs. metachronous) | 1.13 (0.94–1.37) | 0.199 | 1.24 (1.01–1.53) | 0.039 |
| Solitary lesion (no vs. yes) | 0.65 (0.50–0.84) | 0.001 | 0.81 (0.61–1.07) | 0.140 |
| Lung metastasis (absent vs. present) | 0.90 (0.76–1.08) | 0.255 | 1.04 (0.77–1.41) | 0.802 |
| Liver metastasis (absent vs. present) | 1.39 (1.16–1.67) | <0.001 | 1.51 (1.13–2.00) | 0.005 |
| Bone metastasis (absent vs. present) | 1.20 (1.01–1.44) | 0.039 | 1.31 (1.00–1.73) | 0.055 |
| Number of involved sites (one vs. two or more) | 1.39 (1.16–1.67) | <0.001 | 0.97 (0.72–1.29) | 0.814 |
| Treatment modality (CT vs. CT + LT) | 0.67 (0.55–0.82) | <0.001 | 0.68 (0.55–0.85) | <0.001 |
| BMI | 0.001* | 0.003* |
| Underweight vs. normal weight | 0.84 (0.67–1.04) | 0.112 | 0.90 (0.72–1.12) | 0.330 |
| Underweight vs. overweight/obese | 0.62 (0.48–0.81) | <0.001 | 0.64 (0.49–0.84) | 0.001 |

### Table 3 Univariate and multivariate analyses of covariates associated with progression-free survival in patients with metastatic NPC

| Variable | Univariate | Multivariate |
|----------|------------|--------------|
|          | HR (95% CI) | P | HR (95% CI) | P |
| Age (<45 years vs. ≥45 years) | 1.01 (0.87–1.18) | 0.863 | 1.03 (0.88–1.20) | 0.760 |
| Sex (men vs. women) | 1.04 (0.85–1.27) | 0.730 | 1.04 (0.84–1.27) | 0.745 |
| UICC T category (T1–2 vs. T3–4) | 0.92 (0.79–1.07) | 0.289 | 0.92 (0.78–1.07) | 0.274 |
| UICC N category (N0–1 vs. N2–3) | 1.23 (1.05–1.43) | 0.009 | 1.29 (1.10–1.51) | 0.002 |
| Metastasis onset (synchronous vs. metachronous) | 1.04 (0.88–1.23) | 0.647 | 1.17 (0.98–1.39) | 0.091 |
| Solitary lesion (no vs. yes) | 0.69 (0.55–0.87) | 0.001 | 0.87 (0.68–1.12) | 0.281 |
| Lung metastasis (absent vs. present) | 0.87 (0.75–1.02) | 0.083 | 0.98 (0.76–1.27) | 0.900 |
| Liver metastasis (absent vs. present) | 1.50 (1.27–1.77) | <0.001 | 1.50 (1.19–1.90) | 0.001 |
| Bone metastasis (absent vs. present) | 1.27 (1.09–1.48) | 0.003 | 1.33 (1.05–1.68) | 0.019 |
| Number of involved sites (one vs. two or more) | 1.47 (1.25–1.72) | <0.001 | 1.08 (0.84–1.38) | 0.556 |
| Treatment modality (CT vs. CT + LT) | 0.68 (0.57–0.81) | <0.001 | 0.70 (0.58–0.85) | 0.001 |
| BMI | 0.139* | 0.407* |
| Underweight vs. normal weight | 0.87 (0.72–1.06) | 0.141 | 0.91 (0.75–1.11) | 0.367 |
| Underweight vs. overweight/obese | 0.80 (0.64–1.00) | 0.042 | 0.86 (0.68–1.08) | 0.181 |

UICC Union of International Cancer Control; CT chemotherapy; LT local therapy; BMI body mass index; HR hazard ratio; CI confidence interval

* P value with respect to the significance of differential prognosis between BMI subgroups

---

Li et al. Chin J Cancer (2016) 35:75
local therapy. Finally, the applied modes of chemotherapy and local therapy varied, which might have a confounding effect. For these reasons, our findings need to be validated in a multi-institutional prospective study.

Conclusions
This study showed that, for patients receiving palliative chemotherapy, overweight or obese at baseline was associated with longer OS compared with underweight or normal weight. This association was similar across patient subgroups and seemed pronounced in patients with bone metastasis and in those who received chemotherapy only. These data emphasize the link between malnutrition and the survival of patients with metastatic NPC and suggest that nutritional intervention may be recommended for underweight and normal weight patients.

Abbreviations
NPC: nasopharyngeal carcinoma; BMI: body mass index; PFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval.

Table 4 Multiple-adjusted HRs for OS by baseline BMI level, stratified by covariates

| Stratification covariate | No. of patients | Underweight (HR\(^a\)) | Normal weight [HR (95% CI)]\(^b\) | Overweight/obese [HR (95% CI)]\(^b\) | \(P^b\) |
|-------------------------|-----------------|------------------------|-------------------------------------|-------------------------------------|------|
| Age (years)              |                 |                        |                                     |                                     |      |
| <45                      | 419             | 1.0                    | 1.01 (0.74–1.38)                    | 0.74 (0.50–1.09)                    | 0.675|
| ≥45                      | 400             | 1.0                    | 0.76 (0.55–1.06)                    | 0.54 (0.37–0.79)                    |      |
| Sex                      |                 |                        |                                     |                                     |      |
| Men                      | 681             | 1.0                    | 0.82 (0.64–1.04)                    | 0.59 (0.44–0.79)                    | 0.680|
| Women                    | 138             | 1.0                    | 1.29 (0.67–2.45)                    | 0.93 (0.45–1.94)                    |      |
| UICC T category          |                 |                        |                                     |                                     |      |
| T1–2                     | 369             | 1.0                    | 0.84 (0.60–1.17)                    | 0.78 (0.52–1.17)                    | 0.471|
| T3–4                     | 450             | 1.0                    | 0.88 (0.65–1.19)                    | 0.49 (0.34–0.70)                    |      |
| UICC N category          |                 |                        |                                     |                                     |      |
| N0–1                     | 417             | 1.0                    | 0.83 (0.61–1.14)                    | 0.55 (0.37–0.82)                    | 0.501|
| N2–3                     | 402             | 1.0                    | 0.86 (0.60–1.18)                    | 0.67 (0.46–0.98)                    |      |
| Metastasis onset         |                 |                        |                                     |                                     |      |
| Synchronous              | 272             | 1.0                    | 0.94 (0.60–1.49)                    | 0.55 (0.33–0.90)                    | 0.551|
| Metachronous             | 547             | 1.0                    | 0.80 (0.62–1.04)                    | 0.67 (0.48–0.92)                    |      |
| Lung metastasis          |                 |                        |                                     |                                     |      |
| Absent                   | 469             | 1.0                    | 0.92 (0.69–1.24)                    | 0.66 (0.46–0.95)                    | 0.761|
| Present                  | 350             | 1.0                    | 0.78 (0.54–1.12)                    | 0.62 (0.40–0.94)                    |      |
| Liver metastasis         |                 |                        |                                     |                                     |      |
| Absent                   | 574             | 1.0                    | 0.70 (0.54–0.91)                    | 0.45 (0.32–0.62)                    | 0.098|
| Present                  | 245             | 1.0                    | 1.39 (0.22–2.19)                    | 1.46 (0.88–2.43)                    |      |
| Bone metastasis          |                 |                        |                                     |                                     |      |
| Absent                   | 382             | 1.0                    | 0.83 (0.58–1.18)                    | 0.76 (0.50–1.14)                    | 0.051|
| Present                  | 437             | 1.0                    | 0.91 (0.68–1.23)                    | 0.57 (0.39–0.82)                    |      |
| Solitary lesion          |                 |                        |                                     |                                     |      |
| No                       | 701             | 1.0                    | 0.90 (0.72–1.14)                    | 0.60 (0.45–0.80)                    | 0.062|
| Yes                      | 118             | 1.0                    | 0.35 (0.14–0.86)                    | 0.44 (0.17–1.13)                    |      |
| Number of involved sites |                 |                        |                                     |                                     |      |
| One                      | 545             | 1.0                    | 0.72 (0.57–0.99)                    | 0.53 (0.38–0.74)                    | 0.331|
| Two or more              | 274             | 1.0                    | 1.11 (0.75–1.66)                    | 0.84 (0.52–1.33)                    |      |
| Treatment modality       |                 |                        |                                     |                                     |      |
| CT                       | 607             | 1.0                    | 0.92 (0.71–1.19)                    | 0.56 (0.41–0.77)                    | 0.055|
| CT + LT                  | 212             | 1.0                    | 0.74 (0.46–1.21)                    | 0.89 (0.52–1.52)                    |      |

OS overall survival; BMI: body mass index; UICC Union of International Cancer Control; CT chemotherapy; LT local therapy; HR hazard ratio; CI confidence interval

\(^a\) Adjusted for age, sex, UICC T category, UICC N category, onset of metastasis, solitary lesion, lung metastasis, liver metastasis, bone metastasis, number of involved sites, and treatment modality, excluding stratification covariate

\(^b\) \(P\) for interaction
Authors’ contributions

WL and LJS contributed to the data collection and analysis and wrote the manuscript. TC, QXS and YZ contributed to the data collection and helped write the final draft. MW contributed to the data analysis. WHS, CC, CCF and YFX helped write the final draft. PHW contributed to the study design and analysis and was involved in drafting the manuscript. All authors read and approved the final manuscript.

Author details

1 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong, P. R. China. 2 Department of Medical Imaging, Sichuan Cancer Hospital and Institute, Second People’s Hospital of Sichuan Province, Chengdu 610041, Sichuan, P. R. China.

Acknowledgements and funding

We thank Nan-Qiao Cai for providing support on statistics and Juan Nie and Tom Liu for critically reading and revising this manuscript. This study was supported by the grant from the National High Technology Research and Development Program of China (863 Program; No. 2012AA022701). The funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 14 September 2015   Accepted: 22 July 2016

Published online: 09 August 2016

References

1. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1765–77.
2. Wei KR, Zheng RS, Zhang SW, Liang ZH, Ou ZX, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China in 2010. Chin J Cancer. 2014;33(8):381–7.
3. Zhang LF, Li YH, Xie SH, Ling W, Chen SH, Liu Q, et al. Incidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Shihui County, Guangdong Province, South China: an age-period-cohort analysis. Chin J Cancer. 2015;34(6):15.
4. Chiesa F, De Paoli F. Distant metastases from nasopharyngeal cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63(4):214–6.
5. Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009;27(22):3884–90.
6. Fang FM, Tsai WL, Chien CY, Chen HC, Hsu HC, Huang TL, et al. Pretreatment quality of life as a predictor of distant metastasis and survival for patients with nasopharyngeal carcinoma. J Clin Oncol. 2010;28(8):4384–9.
7. Shen LJ, Wang SY, Xie GF, Zeng Q, Chen C, Dong AN, et al. Subdivision of M category for nasopharyngeal carcinoma with synchronous metastasis: time to expand the M categorization system. Chin J Cancer. 2015;34:40.
8. Razak AR, Siu LL, Liu FF, Ito E, O’Sullivan B, Chan K. Nasopharyngeal carcinoma: the next challenges. Eur J Cancer. 2010;46(11):1967–76.
9. Bensouda Y, Kaikani W, Ahbeddou N, Rahalli R, Jabri M, Mraibi H, et al. Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otolaryngol Head Neck Dis. 2011;1(2):79–85.
10. Hu JY, Yi W, Xia YF, Gao J, Liu ZG, Tao YL. Impact of pretherapy body mass index on prognosis of nasopharyngeal carcinoma. Chin J Cancer (Ai Za Zhi). 2009;28(10):1043–8 (in Chinese).
11. Shen GP, Xu FH, He F, Ruan HL, Cui C, Chen LZ, et al. Pretreatment lifestyle behaviors as survival predictors for patients with nasopharyngeal carcinoma. PLoS One. 2012;7(5):e36515.
12. Pan CC, Lu J, Chen P, Li J, Xin YD, Zhao M, et al. Evaluation of the prognostic significance of refinement and stratification of distant metastasis status in 1016 cases of nasopharyngeal carcinoma. Zhonghua Zhong Liu Za Za Zhi. 2013;35(8):595–9 (in Chinese).
13. Mao YR, Xie FY, Liu LZ, Sun Y, Li L, Tang LG, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;73(5):1326–34.
14. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–63.
15. Shen LJ, Chen C, Li BF, Gao J, Xia YF. High weight loss during radiation treatment changes the prognosis in under-/normal weight nasopharyngeal carcinoma patients for the worse: a retrospective analysis of 2433 cases. PLoS One. 2013;8(7):e68660.
16. Huang PY, Wang CT, Cao KJ, Guo X, Guo L, Mo HY, et al. Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: findings from a randomised trial. Eur J Cancer. 2013;49(8):1923–31.
17. Pan C, He N, Zhao M, Gu Y, Huang Z, Li W, et al. Subdividing the M1 stage of liver metastasis for nasopharyngeal carcinoma to better predict metastatic survival. Med Oncol. 2011;28(4):1349–55.
18. O’Shea D, Cawood TJ, O’Farrelly C, Lynch L. Natural killer cells in obesity: impaired function and increased susceptibility to the effects of cigarette smoke. PLoS One. 2010;5(1):e6660.
19. He JR, Shen GP, Ren ZF, Qin H, Cui C, Zhang Y, et al. Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma. Head Neck. 2012;34(12):1769–76.
20. Van Cutsem E, Arends J. The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs. 2005;9(Suppl. 2):S1–63.
21. Capuano G, Gentile PC, Biancardi F, Tosti M, Palladino A, Di Palma M. Prevalence and influence of malnutrition on quality of life and performance status in patients with locally advanced head and neck cancer before treatment. Support Care Cancer. 2010;18(4):433–7.
22. Kwong DL, Sham JS, Chua DT, Choy DT, Au GK, Wu PM. The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1997;39(3):703–10.
23. Capuano G, Grosso A, Gentile PC, Battista M, Biancardi F, Di Palma A, et al. Influence of weight loss on outcomes in patients with head and neck cancer undergoing concomitant chemoradiotherapy. Head Neck. 2008;30(4):503–8.
24. Ghadjar P, Simcock M, Zimmerman F, Bertz M, Bodis S, Bernier J, et al. Predictors of severe late radiotherapy-related toxicity after hypofractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94). Radiother Oncol. 2012;104(2):213–8.
25. Couch M, Lai V, Cannon T, Guttridge D, Zanation A, George J, et al. Cancer cachexia syndrome in head and neck cancer patients: part I. Diagnosis, impact on quality of life and survival, and treatment. Head Neck. 2007;29(4):401–11.
26. Sze HC, Ng WT, Chan OS, Shum TC, Chan LL, Lee AW. Radical radiotherapy for nasopharyngeal carcinoma in elderly patients: the importance of comorbidity. Oral Oncol. 2012;48(2):162–7.
27. Ramakrishnan Y, Palen V, Shah R, Steen IN, Wight RG, Kelly CC. Comorbidity in nasopharyngeal carcinoma: a preliminary communication on the prevalence, descriptive distribution and impact on outcome. Clin Otolaryngol. 2007;32(6):484–9.
28. Kim JM, Kim YJ, Lee KW, Chang H, Lee JD, Kim KJ, et al. The early discontinuation of palliative chemotherapy in older patients with cancer. Support Care Cancer. 2014;22(3):773–81.
29. Isserlin EA, Capra S, Bauer JD. Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. Br J Cancer. 2004;91(3):447–52.
30. Canada T. Clinical dilemma in cancer: is tumor growth during nutrition support significant? Nutr Clin Pract. 2002;17(4):246–8.
31. Locher JL, Bonner JA, Carroll WR, Caudell JJ, Keith JN, Kilgore ML, et al. Prophylactic percutaneous endoscopic gastrostomy tube placement in treatment of head and neck cancer: a comprehensive review and call for evidence-based medicine. JPEN J Parenter Enteral Nutr. 2011;35(3):365–74.
32. Wermker K, Jung S, Huppmeier L, Joos U, Kleinheinz J. Prediction model for early percutaneous endoscopic gastrostomy (PEG) in head and neck cancer treatment. Oral Oncol. 2012;48(4):355–60.
33. Isenring EA, Teleni L. Nutritional counseling and nutritional supplements: a cornerstone of multidisciplinary cancer care for cachectic patients. Curr Opin Support Palliat Care. 2013;7(4):390–5.
34. Rabinovitch R, Grant B, Berkey BA, Raben D, Ang KK, Fu KK, et al. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head Neck. 2006;28(4):287–96.
35. Orphanidou C, Biggs K, Johnston ME, Wright JR, Bowman A, Hotte SJ, et al. Prophylactic feeding tubes for patients with locally advanced head-and-neck cancer undergoing combined chemotherapy and radiotherapy-systematic review and recommendations for clinical practice. Curr Oncol. 2011;18(4):e191–201.